Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease
{{output}}
Aims: To assess the association between remaining persistent with once-weekly glucagon-like peptide-1 receptor agonists (OW GLP-1 RAs) and the risk of major adverse cardiovascular events (MACE) among patients with type 2 diabetes... ...
